Qube Research & Technologies LTD Alpine Immune Sciences, Inc. Transaction History

Qube Research & Technologies LTD

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$17.75 - $41.6 $753,363 - $1.77 Million	-42,443 Reduced 20.63%	163,323 $6.47 Million
Q4 2023 Feb 13, 2024	BUY	$8.54 - $20.22 $1.67 Million - $3.96 Million	195,696 Added 1943.36%	205,766 $3.92 Million
Q3 2023 Nov 13, 2023	BUY	$10.13 - $13.98 $102,009 - $140,778	10,070 New	10,070 $115,000
Q2 2021 Aug 13, 2021	SELL	$8.81 - $15.03 $128,291 - $218,866	-14,562 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$10.02 - $13.92 $320,579 - $445,356	-31,994 Reduced 68.72%	14,562 $154,000
Q4 2020 Feb 16, 2021	BUY	$7.42 - $15.96 $68,108 - $146,496	9,179 Added 24.56%	46,556 $587,000
Q3 2020 Nov 12, 2020	BUY	$7.15 - $11.5 $267,245 - $429,835	37,377 New	37,377 $329,000

56.2K

Ticker ALPN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 44,006,700
Description
Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28...

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

Stay updated on Qube Research & Technologies LTD with notifications on news.